^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    JAK2 rearrangement

    i
    Other names: JTK10, THCYT3, JAK2, Janus Kinase 2, Tyrosine-Protein Kinase JAK2, JAK-2
    Entrez ID:
    3717
    Related biomarkers:
    Expression
    Mutation
    CNA
    Fusion
    Others
    Associations

    News

    Trials
    4years
    Ruxolitinib in Treating Patients With Hypereosinophilic Syndrome or Primary Eosinophilic Disorders (clinicaltrials.gov)
    P2, N=25, Recruiting, Jason Robert Gotlib | Not yet recruiting --> Recruiting | Trial completion date: Jun 2024 --> Oct 2023 | Trial primary completion date: Apr 2021 --> Apr 2023
    Clinical • Enrollment open • Trial completion date • Trial primary completion date
    |
    JAK2 (Janus kinase 2) • ETV6 (ETS Variant Transcription Factor 6) • PCM1 (Pericentriolar Material 1)
    |
    JAK2 mutation • JAK2 rearrangement
    |
    Jakafi (ruxolitinib)